# Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis

> **NCT04755023** · PHASE2 · COMPLETED · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 53 (actual)

## Conditions studied

- Oligodendroglioma; Oligoastrocytoma

## Interventions

- **DRUG:** Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide

## Key facts

- **NCT ID:** NCT04755023
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-21
- **Primary completion:** 2009-03-15
- **Final completion:** 2010-12-15
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04755023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04755023, "Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT04755023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*